Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: An analysis of systematic reviews

Annals of Internal Medicine

Volumn 161, Issue 7, 2014, Pages 513-518

  Dunn, Adam G ^a   Arachi, Diana ^a   Hudgins, Joel ^b   Tsafnat, Guy ^a   Coiera, Enrico ^a   Bourgeois, Florence T ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ARTICLE; COCHRANE LIBRARY; CONFLICT OF INTEREST; EMBASE; FINANCIAL CONFLICT OF INTEREST; HUMAN; INFLUENZA; MEDLINE; PUBLICATION; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); VALIDITY; ANTAGONISTS AND INHIBITORS; DRUG INDUSTRY; FINANCIAL MANAGEMENT; INFLUENZA, HUMAN; LITERATURE;

ANTIVIRAL AGENTS; CONFLICT OF INTEREST; DRUG INDUSTRY; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; RESEARCH SUPPORT AS TOPIC; RETROSPECTIVE STUDIES; REVIEW LITERATURE AS TOPIC;

EID: 84908115542     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0933     Document Type: Article

References (66)

1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. [PMID: 23235689] doi:10.1002/14651858.MR000033.pub2
2. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JP. Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest. 2010;40:172-82. [PMID: 20050879] doi:10.1111/j.1365-2362.2009.02240.x
3. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-8. [PMID: 12928469]
4. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA. 2006; 295:2270-4. [PMID: 16705108]
5. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008;5:e217. [PMID: 19067477] doi:10.1371/journal.pmed.0050217
6. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med. 2010;153:158-66. [PMID: 20679560] doi:10.7326/0003-4819-153-3-201008030-00006
7. Dwan K, Gamble C, Williamson PR, Kirkham JJ; Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias-an updated review. PLoS One. 2013;8:e66844. [PMID: 23861749] doi:10.1371/journal.pone.0066844
8. Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One. 2009;4:e5826. [PMID: 19503811] doi:10.1371 /journal.pone.0005826
9. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007;4:e184. [PMID: 17550302]
10. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002;325:249. [PMID: 12153921]
11. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry. 2005;162:1957-60. [PMID: 16199844]
12. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004; 170:477-80. [PMID: 14970094]
13. Bes-Rastrollo M, Schulze MB, Ruiz-Canela M, Martinez-Gonzalez MA. Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews. PLoS Med. 2013;10:e1001578. [PMID: 24391479] doi:10.1371 /journal.pmed.1001578
14. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006;333:782. [PMID: 17028106]
15. Krumholz HM, Jackevicius CA, Ross JS. Tamiflu: 14 flu seasons and still questions [Editorial]. BMJ. 2013;346:f547. [PMID: 23355545] doi:10.1136 /bmj.f547
16. Aoki FY, Hayden FG. The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic [Editorial]. J Infect Dis. 2013;207:547-9. [PMID: 23204176] doi:10.1093/infdis/jis727
17. Groves T. What does oseltamivir do, and how will we know? BMJ. 2013; 347:f4687. [PMID: 23884974] doi:10.1136/bmj.f4687
18. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ. 2013;346: f2865. [PMID: 23766480] doi:10.1136/bmj.f2865
19. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012;9: e1001201. [PMID: 22505850] doi:10.1371/journal.pmed.1001201
20. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965. [PMID: 22258996] doi:10.1002/14651858.CD008965.pub3
21. Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. BMJ. 2012;344:d7898. [PMID: 22252039] doi:10.1136/bmj.d7898
22. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. [PMID: 24811411] doi:10.1136/bmj.g2545
23. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965. [PMID: 24718923] doi:10.1002/14651858.CD008965.pub4
24. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547. [PMID: 24811412] doi:10.1136/bmj.g2547
25. Krumholz HM. Neuraminidase inhibitors for influenza [Editorial]. BMJ. 2014;348:g2548. [PMID: 24811413] doi:10.1136/bmj.g2548
26. Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ. 2014;348:g2263. [PMID: 24721793] doi:10.1136/bmj.g2263
27. Cohen D. Oseltamivir: another case of regulatory failure? BMJ. 2014;348: g2591. doi:10.1136/bmj.g2591
28. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353:1363-73. [PMID: 16192481]
29. Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med. 2010;38:e43-51. [PMID: 19935416] doi:10.1097/CCM.0b013e3181c85229
30. Jones M, Del Mar C. Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf. 2006;5:603-8. [PMID: 16907649]
31. Chan AW. Bias, spin, and misreporting: time for full access to trial protocols and results. PLoS Med. 2008;5:e230. [PMID: 19067481] doi:10.1371/journal .pmed.0050230
32. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010;303:2058-64. [PMID: 20501928] doi:10.1001 /jama.2010.651
33. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998; 316:61-6. [PMID: 9451274]
34. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101. [PMID: 7786990]
35. Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med. 2009;151: 464-73. [PMID: 19652173]
36. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207:553-63. [PMID: 23204175] doi:10.1093/infdis/jis726
37. Beck CR, Sokal R, Arunachalam N, Puleston R, Cichowska A, Kessel A, et al; UK Antiviral Effectiveness Review Group. Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic. Influenza Other Respir Viruses. 2013;7 Suppl 1:14-24. [PMID: 23279893] doi:10.1111/irv.12048
38. Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract. 2013;30: 125-33. [PMID: 22997224] doi:10.1093/fampra/cms059
39. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106. [PMID: 19995812] doi:10.1136 /bmj.b5106
40. Schmidt AF, Groenwold RH, van Delden JJ, van der Does Y, Klungel OH, Roes KC, et al. Justification of exclusion criteria was underreported in a review of cardiovascular trials. J Clin Epidemiol. 2014;67:635-44. [PMID: 24613498] doi:10.1016/j.jclinepi.2013.12.005
41. Roundtree AK, Kallen MA, Lopez-Olivo MA, Kimmel B, Skidmore B, Ortiz Z, et al. Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review. J Clin Epidemiol. 2009;62:128-37. [PMID: 19013763] doi:10.1016 /j.jclinepi.2008.08.003
42. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007;335: 1202-5. [PMID: 18024482]
43. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996;12:209-37. [PMID: 8707496]
44. Payne D. Tamiflu: the battle for secret drug data. BMJ. 2012;345:e7303. [PMID: 23109482] doi:10.1136/bmj.e7303
45. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? BMJ. 2014;348:g171. [PMID: 24423895] doi:10.1136/bmj.g171
46. Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007;147:224-33. [PMID: 17638714]
47. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2007:CD002744. [PMID: 17253479]
48. Postma MJ, Beardsworth P, Wilschut JC. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes. J Med Econ. 2008;11:743-68. [PMID: 19450079] doi:10.3111/13696990802505557
49. Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton NJ, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1-265, iii-iv. [PMID: 19954682] doi:10.3310/hta13580
50. Falagas ME, Vouloumanou EK, Baskouta E, Rafailidis PI, Polyzos K, Rello J. Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents. 2010;35:421-30. [PMID: 20185273] doi:10.1016/j.ijantimicag.2010.01.006
51. Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Rello J. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1330-46. [PMID: 20488984] doi:10.1093/jac/dkq158
52. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol. 2011;205:10-8. [PMID: 21345415] doi:10.1016/j.ajog.2010.12.033
53. Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011;62:14-25. [PMID: 20950645] doi:10.1016/j .jinf.2010.10.003
54. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395-404. [PMID: 24815805] doi:10.1016/S2213-2600(14)70041-4
55. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367: 303-13. [PMID: 16443037]
56. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ. 2009;339:b3172. [PMID: 19666987] doi:10.1136/bmj.b3172
57. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:537-45. [PMID: 19665930] doi:10.1016/S1473-3099(09)70199-9
58. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2010:CD001265. [PMID: 20166059] doi:10.1002/14651858.CD001265.pub3
59. Jagannath VA, Asokan GV, Fedorowicz Z, Singaram JS, Lee TW. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2010:CD008139. [PMID: 20238363] doi:10.1002/14651858.CD008139.pub2
60. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2012;1:CD002744. [PMID: 22258949] doi:10.1002/14651858 .CD002744.pub3
61. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;4:CD002744. [PMID: 22513907] doi:10.1002/14651858.CD002744.pub4
62. Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156:512-24. [PMID: 22371849] doi:10.7326/0003-4819-156-7-201204030-00411
63. Jagannath VA, Asokan GV, Fedorowicz Z, Lee TW. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2014;2:CD008139. [PMID: 24515341] doi:10.1002/14651858.CD008139.pub3
64. Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the real world data. BMJ. 2014;348:g2371. [PMID: 24811409] doi:10.1136 /bmj.g2371
65. Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, et al. Safety and immunogenicity of whole-virus, alum-adjuvanted wholevirus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine. 2009;28:171-8. [PMID: 19799843] doi:10.1016/j.vaccine .2009.09.103
66. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008;8:650-8. [PMID: 18922487] doi:10.1016/S1473-3099(08)70232-9